Adicet Bio, Inc. (ACET)
$8.88-$0.13 (-1.44%) Today
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 9 | 153,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
23 Form 4 filings on record, the earliest from Jun 11, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lloyd Klickstein - Officer | Grant or award | Stock Option (Right to Buy) | 18,300 | $0.00 | - | |
| Chen Schor - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
 Blake Aftab - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Steve Dubin | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
 Jeffrey Chodakewitz | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Michael Grissinger | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Andrew Sinclair | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Katie Peng | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| Lloyd Klickstein | Grant or award | Stock Option (Right to Buy) | 4,200 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Common Stock | 250,000 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Other | Pre-Funded Warrant (Right to Buy) | 250,000 | - | - | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,577 | $7.04 | $525K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,268 | $7.21 | $535K | |
| RA CAPITAL MANAGEMENT, L.P. | Open-market purchase | Common Stock | 74,751 | $7.27 | $543K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 29,319 | $6.53 | $191K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 2,400 | $6.38 | $15K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 32,523 | $6.29 | $205K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 40,416 | $6.52 | $264K | |
| Brian Nicholas Harvey - Officer | Grant or award | Stock Option (Right to Buy) | 43,361 | $0.00 | - | |
| Chen Schor - Officer | Grant or award | Stock Option (Right to Buy) | 468,555 | $0.00 | - | |
| Julia D. Maltzman - Officer | Grant or award | Stock Option (Right to Buy) | 72,555 | $0.00 | - | |
| Don Healey - Officer | Grant or award | Stock Option (Right to Buy) | 43,361 | $0.00 | - | |
| Blake Aftab - Officer | Grant or award | Stock Option (Right to Buy) | 72,555 | $0.00 | - | |
| Blake Aftab - Officer | Tax withholding / forfeiture | Common Stock | 535 | $8.44 | $5K | |
| Don Healey - Officer | Tax withholding / forfeiture | Common Stock | 535 | $8.44 | $5K | |
| Chen Schor - Officer | Tax withholding / forfeiture | Common Stock | 1,755 | $8.44 | $15K | |
| Brian Nicholas Harvey - Officer | Tax withholding / forfeiture | Common Stock | 546 | $8.44 | $5K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Common Stock | 1,500,000 | $16.00 | $1.50M | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Common Stock | 3,500,000 | $16.00 | $3.50M | |
| Steve Dubin | Grant or award | Common Stock | 5,900 | $0.00 | - | |
| Steve Dubin | Grant or award | Stock Option (Right to Buy) | 26,400 | $0.00 | - |
Adicet Bio, Inc. (ACET) had 9 insider filings in the last 90 days, with the most recent on 2026-08-07. The full record for ACET runs to 23 Form 4 filings, the earliest from 2025-06-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ACET were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of ACET were filed in the last 90 days. 4 sales are on record for this company.
This page tracks ACET Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ACET to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
